LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy - Takeaways - MDSpire

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • By

  • Juan Zhang

  • Mingzhen Zhou

  • Ziyue Jin

  • Wenyan Cao

  • Xuena Zhang

  • Fanlai Meng

  • Haiyan Wei

  • Jie Shen

  • July 1, 2026

  • 0 min

Share

  • 1

    The study investigates LAG-3, CD8, and PD-1 in hepatocellular carcinoma patients treated with Lenvatinib and anti-PD-1 antibodies.

  • 2

    Data from 77 HCC patients revealed varying treatment responses, with 1 complete response and 23 partial responses after combination therapy.

  • 3

    Age, cirrhosis status, and ECOG performance status were statistically linked to treatment response in HCC patients.

  • 4

    High pan-immune-inflammation value and low LAG-3+ cell counts were identified as independent prognostic factors for overall survival.

  • 5

    Low albumin levels and high neutrophil-to-lymphocyte ratio were independent prognostic factors for progression-free survival in treated patients.

Original Source(s)

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • by Juan Zhang, Mingzhen Zhou, Ziyue Jin, Wenyan Cao, Xuena Zhang, Fanlai Meng, Haiyan Wei, Jie Shen

  • July 1, 2026

Related Content

Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis